Ibogaine derivatives- Terran Biosciences
Alternative Names: Ibogaine derivativesLatest Information Update: 12 Dec 2023
At a glance
- Originator Terran Biosciences
- Class Antipsychotics; Drug withdrawal therapies; Ethers; Heterocyclic compounds with 4 or more rings; Indoles; Neuropsychotherapeutics; Rauwolfia alkaloids; Small molecules
- Mechanism of Action Excitatory amino acid antagonists; NMDA receptor antagonists; Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neurological disorders; Psychiatric disorders
Most Recent Events
- 08 Dec 2023 Terran Biosciences receives patent allowance for novel form of tabernanthalog monofumarate and the method of use for treating neurological and psychiatric disorders in USA
- 05 May 2023 Preclinical trials in Neurological disorders in USA (unspecified route) prior to May 2023
- 05 May 2023 Preclinical trials in Psychiatric disorders in USA (unspecified route) prior to May 2023